PL367829A1 - Testowanie wrażliwości wirusów na leki - Google Patents

Testowanie wrażliwości wirusów na leki

Info

Publication number
PL367829A1
PL367829A1 PL02367829A PL36782902A PL367829A1 PL 367829 A1 PL367829 A1 PL 367829A1 PL 02367829 A PL02367829 A PL 02367829A PL 36782902 A PL36782902 A PL 36782902A PL 367829 A1 PL367829 A1 PL 367829A1
Authority
PL
Poland
Prior art keywords
enzyme
activity
present
sample
sensitivity profile
Prior art date
Application number
PL02367829A
Other languages
English (en)
Other versions
PL209075B1 (pl
Inventor
Clas Källander
Anders Malmsten
Simon Gronowitz
Xingwu Shao
Original Assignee
Cavidi Tech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cavidi Tech Ab filed Critical Cavidi Tech Ab
Publication of PL367829A1 publication Critical patent/PL367829A1/pl
Publication of PL209075B1 publication Critical patent/PL209075B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem niniejszego wynalazku jest sposób testowania fenotypowej podatności na lek u ssaka zakażonego wirusem w otoczce przez wykonanie testu na enzymie znajdującym się w wirusie zaopatrzonym w otoczkę, takim jak wirus HIV, uzyskanym z próbki materiału biologicznego, takiego jak krew lub osocze, pobranego od tego osobnika. Sposób obejmuje etapy: a) dodania do próbki środka dezaktywującego enzymy w celu wyeliminowania aktywności polimeraz innych niż obecne w wirionie w otoczce b) usunięcia środka dezaktywującego enzymy, przeciwciał blokujących aktywność enzymów, inhibitorów aktywności enzymów endogennych i leków przeciwwirusowych c) dokonania lizy cząstki wirusa w celu uwolnienia enzymu d) odzyskania zatężonego, oczyszczonego enzymu wirusowego, takiego jak odwrotna transkryptaza (RT) HIV z etapu c) i oznaczenia profilu wrażliwości osobnika na lek na podstawie odzyskanego enzymu poprzez zastosowanie czułych testów enzymatycznych. Profil wrażliwości na lek można wykorzystać do doboru leczenia farmakologicznego. Przedmiotem niniejszego wynalazku jest także opakowanie handlowe.
PL367829A 2001-06-14 2002-06-14 Sposób testowania fenotypowej wrażliwości na lek oraz zestaw do określania fenotypowej wrażliwości na lek PL209075B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29776401P 2001-06-14 2001-06-14
PCT/SE2002/001156 WO2002103040A1 (en) 2001-06-14 2002-06-14 Viral drug susceptibility testing

Publications (2)

Publication Number Publication Date
PL367829A1 true PL367829A1 (pl) 2005-03-07
PL209075B1 PL209075B1 (pl) 2011-07-29

Family

ID=23147646

Family Applications (1)

Application Number Title Priority Date Filing Date
PL367829A PL209075B1 (pl) 2001-06-14 2002-06-14 Sposób testowania fenotypowej wrażliwości na lek oraz zestaw do określania fenotypowej wrażliwości na lek

Country Status (17)

Country Link
US (1) US7875422B2 (pl)
EP (1) EP1395676B1 (pl)
JP (1) JP4455054B2 (pl)
CN (1) CN1539022B (pl)
AP (1) AP1592A (pl)
AT (1) ATE316150T1 (pl)
AU (1) AU2002309447B2 (pl)
BR (1) BRPI0210361B8 (pl)
DE (1) DE60208788T2 (pl)
EA (1) EA006161B1 (pl)
ES (1) ES2257553T3 (pl)
MX (1) MXPA03011564A (pl)
OA (1) OA12620A (pl)
PL (1) PL209075B1 (pl)
PT (1) PT1395676E (pl)
WO (1) WO2002103040A1 (pl)
ZA (1) ZA200309551B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523088A (ja) * 2013-06-26 2016-08-08 フィロジカ リミテッドＰｈｙｌｏｇｉｃａ Ｌｉｍｉｔｅｄ ペプチドの細胞輸送をモニタリングする方法
BR112019027993A2 (pt) * 2017-07-04 2020-07-07 Cavidi Ab métodos para avaliar a susceptibilidade de um vírus ao tratamento com um fármaco inibidor de uma enzima do vírus do tipo selvagem, para avaliar se um paciente tratado para uma infecção viral tem necessidade de alterar a terapia farmacológica com um fármaco inibidor da enzima viral e para determinar a carga de um vírus em uma amostra do paciente e a dita resistência do vírus ao tratamento com um fármaco inibidor de uma enzima do vírus do tipo selvagem, e, sistema
CN108896759B (zh) * 2018-06-27 2020-05-19 南京医科大学 受试物致敏性检测方法及其试剂盒

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707439A (en) * 1984-10-26 1987-11-17 The United States Of America As Represented By The Department Of Health And Human Services Screening test for reverse-transcriptase containing virus such as non-A, non-B hepatitis, NANBH
US6268123B1 (en) * 1993-06-01 2001-07-31 Retro-Tech Gmbh Direct and biochemically functional detection process of retrovirus in biological samples
DE19608687A1 (de) * 1996-03-06 1997-09-11 Retro Tech Gmbh Verfahren und Test-Kit für den nichtradioaktiven, enzymatischen Nachweis von Reverser Transkriptase
SE9902410D0 (sv) * 1999-06-24 1999-06-24 Cavidi Tech Ab Reverse transcriptase assay kit, use thereof and method for analysis of RT activity in biological samples
SE0001132D0 (sv) * 2000-03-29 2000-03-29 Cavidi Tech Ab Method of concentrating and recovering a viral enzyme activity from biological samples

Also Published As

Publication number Publication date
EP1395676B1 (en) 2006-01-18
AU2002309447B2 (en) 2007-05-24
JP4455054B2 (ja) 2010-04-21
BR0210361A (pt) 2004-06-22
PT1395676E (pt) 2006-06-30
AP2003002923A0 (en) 2003-12-31
BR0210361B1 (pt) 2014-12-30
ZA200309551B (en) 2005-02-23
EA006161B1 (ru) 2005-10-27
AP1592A (en) 2006-03-20
EA200301244A1 (ru) 2004-06-24
DE60208788D1 (de) 2006-04-06
JP2004530433A (ja) 2004-10-07
BRPI0210361B8 (pt) 2021-07-27
CN1539022B (zh) 2011-04-13
HK1065070A1 (en) 2005-02-08
US20040170958A1 (en) 2004-09-02
ATE316150T1 (de) 2006-02-15
OA12620A (en) 2006-06-12
CN1539022A (zh) 2004-10-20
ES2257553T3 (es) 2006-08-01
EP1395676A1 (en) 2004-03-10
US7875422B2 (en) 2011-01-25
WO2002103040A1 (en) 2002-12-27
MXPA03011564A (es) 2004-03-18
DE60208788T2 (de) 2006-11-09
PL209075B1 (pl) 2011-07-29

Similar Documents

Publication Publication Date Title
Badr et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells
Onyango et al. Laboratory diagnosis of Ebola hemorrhagic fever during an outbreak in Yambio, Sudan, 2004
de Alwis et al. Immunodominant dengue virus-specific CD8+ T cell responses are associated with a memory PD-1+ phenotype
Auewarakul et al. Uncoating of HIV-1 requires cellular activation
Mayers et al. Characterization of HIV isolates arising after prolonged zidovudine therapy
Parida et al. Serological & virological investigation of an outbreak of
Moss et al. Comparison of the plaque test and reverse transcription nested PCR for the detection of FMDV in nasal swabs and probang samples
Nkengasong et al. Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast
Murugesan et al. Molecular diversity of dengue virus serotypes 1–4 during an outbreak of acute dengue virus infection in Theni, India
Quer et al. Contingent neutrality in competing viral populations
Najioullah et al. Failure and success of HIV tests for the prevention of HIV‐1 transmission by blood and tissue donations
Nouhin et al. Low frequency of acute hepatitis E virus (HEV) infections but high past HEV exposure in subjects from Cambodia with mild liver enzyme elevations, unexplained fever or immunodeficiency due to HIV-1 infection
Okamoto et al. Evaluation of sensitivity of TaqMan RT-PCR for rubella virus detection in clinical specimens
Ponamgi et al. Prevalence of hepatitis C virus (HCV) coinfection in HIV infected individuals in south India and characterization of HCV genotypes
Quer et al. Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection
Davarpanah et al. Hepatitis C virus genotype distribution in Shiraz, southern Iran
PL367829A1 (pl) Testowanie wrażliwości wirusów na leki
Gibbons et al. Silent infections with human immunodeficiency virus type 1 are highly unlikely in multitransfused seronegative hemophiliacs [see comments]
Wasieloski Jr et al. Reverse transcription-PCR detection of LaCrosse virus in mosquitoes and comparison with enzyme immunoassay and virus isolation
Hourfar et al. Human immunodeficiency virus 1 dual‐target nucleic acid technology improves blood safety: 5 years of experience of the German Red Cross blood donor service Baden‐Württemberg–Hessen
Jashes et al. Inhibitory effects of EICAR on infectious pancreatic necrosis virus replication
HUP0101396A2 (hu) Eljárás helikázaktivitással rendelkező, humán papillomavírus-E1 előállítására és alkalmazására
Aramani et al. Efficacy of nucleic acid amplification test (NAT) over enzyme linked immuno sorbent assay (ELISA) in detecting transfusion transmissible infections (TTI) among blood donors at a tertiary care centre
Kondo et al. Genotype of GB virus C/hepatitis G virus by molecular evolutionary analysis
Songjaeng et al. Development of a Singleplex Real-Time Reverse Transcriptase PCR Assay for Pan-Dengue Virus Detection and Quantification. Viruses. 2022; 14